Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT05959551
Recruiting Not applicable

HD-tDCS to Modulate Connectivity

NCT05959551 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Manitoba
Phase
Not applicable
Started
2023-07-01
Last updated
2026-05-01

Condition(s) studied

Electricity; Effects

Investigational drug(s) / intervention(s)

high definition transcranial direct current stimulation (HD-tDCS)

high definition transcranial direct current stimulation (HD-tDCS): HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Study summary

The purpose of the proposed study is to broaden our understanding on the neural effects of High Definition Transcranial Direct Current Stimulation (HD-tDCS) so that its clinical effects can be further improved.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: \- All other than excluded. Exclusion Criteria: * History or susceptibility to any neurological or psychiatric diseases, particularly seizures * abnormal MRI * metal implants or a cardiac pacemaker * pregnant or breastfeeding women

Primary outcome measure(s)

  • change of functional connectivity — 0-11 minutes after the stimulation contrasting baseline (before stimulation)
    Changes in seed-based connectivity originating from the targeted brain regions immediately after the brain stimulation

Trial sites (1)

FacilityCityRegionStatus
University of Manitoba Winnipeg Manitoba Recruiting

More University of Manitoba trials in Canada

tDCS on Parkinson's Disease Cognition Recruiting
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients Recruiting
Perioperative Virtual Reality Intervention for Pain and Anxiety During Vasectomies Recruiting
Closing The Post Fracture Care Gap In Manitoba Active, not recruiting
A Multidisciplinary Investigation of Cardiovascular Benefits of Wild Rice Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05959551 on ClinicalTrials.gov ↗ ← All trials in Canada